HACKENSACK, N.J., Nov. 7,
2018 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR),
engaged in an end-to-end range of research and development
technology solutions and services to improve the development and
use of oncology drugs, today announced that management, will
participate in the 9th annual Craig-Hallum Alpha Select conference
on Thursday, November 15, 2018, in
New York.
Management will be available during the day for one-on-one
meetings. For more information about the conference or to schedule
a one-on-one meeting with management, please contact your
Craig Hallum representative or
Hayden IR at james@haydenir.com.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's TumorGraft
technology platform is a novel approach to personalizing cancer
care based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting
engraftments, or TumorGrafts, in a manner that preserves the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The Company
uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. TumorGrafts are
procured through agreements with a number of institutions in the
U.S. and overseas as well as through Champions' Personalized
Oncology Solutions business. For more information, please
visit www.championsoncology.com.
View original
content:http://www.prnewswire.com/news-releases/champions-oncology-to-participate-in-the-9th-annual-craig-hallum-alpha-select-conference-300745024.html
SOURCE Champions Oncology, Inc.